Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Less than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.

There are currently no proven vaccines or drugs for the prevention of COVID-19. Led by Co-Principal Investigators Nick White and Will Schilling, the COPCOV study is a double-blind, randomised, placebo-controlled trial that will enrol 40,000+ frontline health care workers and staff from Europe, Africa and Asia who have close contact with COVID-19 patients to determine whether chloroquine and hydroxychloroquine are effective in preventing COVID-19.

Sponsored by Oxford, COPCOV is funded by a grant by the COVID-19 Bill & Melinda Gates Foundation, Wellcome and MasterCard Therapeutics Accelerator. 

Nick and Will are joined by COPCOV Investigators Nick Day, Bob Taylor, Phaik Yeong Cheah and James Callery from MORU; Mahidol FTM Dean Asst Prof Weerapong Phumratanaprapin; Prof Yoong Poovorawan (Chulalongkorn); LOMWRU’s Liz Ashley and Mayfong Mayxay; COMRU’s Paul Turner and Arjun Chandna; Piero Olliaro (NDM); Dr Dora Buonfrate (Sacro Cuore Don Calabria Hospital, Italy); Prof Martin Llewelyn (Brighton and Sussex Medical School, UK), and OUCRU Director Prof Guy Thwaites

After being enrolled in the study and giving their fully informed consent, each participant will be randomly selected to receive either chloroquine or a placebo (in Asia) or hydroxychloroquine or a placebo (in Europe and Africa) for 3 months. Half the participants will receive the drug, half will receive a placebo. Neither the study team nor the patient will not know if the participant is taking the drug or a placebo.

MORU’s first COVID-19 response pages are now up on our website. We'll be adding soon COPCOV and the SEB-COV study protocols, FAQs and study sites, and news releases and updates as they come up.

The current pages include Nick White explaining COPCOV’s rationale and aims and COPCOV at a glance, which includes a video of Phaik Yeong Cheah explaining what happens when you enrol in COPCOV.

Similar stories

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

The COVID-19 vaccine: do we know enough to end the pandemic?

@Oxford MORU

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.

Clare Ling awarded honorary FRCPath

Awards & Appointments MORU SMRU

Dr Clare Ling has been made an honorary Fellow of the Royal College of Pathologists (FRCPath). Currently running Shoklo Malaria Research Unit (SMRU) Microbiology department and supporting the unit’s molecular activities, Clare is a clinical scientist who has worked at SMRU on the Thai-Myanmar border since 2012.